Dublin, Ireland – 27 th November 2023 – Priothera Ltd., a Phase 3 clinical stage biotechnology company pioneering the development of its S1P receptor modulator compound mocravimod, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results